[go: up one dir, main page]

RU2010119919A - Кристаллические химиотерапевтические средства - Google Patents

Кристаллические химиотерапевтические средства Download PDF

Info

Publication number
RU2010119919A
RU2010119919A RU2010119919/04A RU2010119919A RU2010119919A RU 2010119919 A RU2010119919 A RU 2010119919A RU 2010119919/04 A RU2010119919/04 A RU 2010119919/04A RU 2010119919 A RU2010119919 A RU 2010119919A RU 2010119919 A RU2010119919 A RU 2010119919A
Authority
RU
Russia
Prior art keywords
crystal
equal
ray
chemotherapeutic products
approximately
Prior art date
Application number
RU2010119919/04A
Other languages
English (en)
Inventor
Майкл Дж. РОЗЕМА (US)
Майкл Дж. Розема
Original Assignee
Эбботт Лэборетриз (Us)
Эбботт Лэборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Лэборетриз (Us), Эбботт Лэборетриз filed Critical Эбботт Лэборетриз (Us)
Publication of RU2010119919A publication Critical patent/RU2010119919A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Кристаллическая форма 1 N-[4-(3-амино-1H-индазол-4-ил)фенил]-N'-(2-фтор-5-метилфенил)мочевины, которая при измерении при приблизительно 25ºC с длиной волны рентгеновского излучения, равной 1,54178 Å, характеризуется порошковой рентгенограммой, имеющей относительные 2θ величины, приблизительно равные 7,8º, 9,1º, 11,0º, 11,8º и 12,1º.

Claims (1)

  1. Кристаллическая форма 1 N-[4-(3-амино-1H-индазол-4-ил)фенил]-N'-(2-фтор-5-метилфенил)мочевины, которая при измерении при приблизительно 25ºC с длиной волны рентгеновского излучения, равной 1,54178 Å, характеризуется порошковой рентгенограммой, имеющей относительные 2θ величины, приблизительно равные 7,8º, 9,1º, 11,0º, 11,8º и 12,1º.
RU2010119919/04A 2007-10-19 2008-10-16 Кристаллические химиотерапевтические средства RU2010119919A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98125307P 2007-10-19 2007-10-19
US60/981,253 2007-10-19

Publications (1)

Publication Number Publication Date
RU2010119919A true RU2010119919A (ru) 2011-11-27

Family

ID=40174807

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010119919/04A RU2010119919A (ru) 2007-10-19 2008-10-16 Кристаллические химиотерапевтические средства

Country Status (18)

Country Link
US (1) US7960564B2 (ru)
EP (1) EP2195301A1 (ru)
JP (1) JP2011500707A (ru)
KR (1) KR20100085987A (ru)
CN (1) CN101827824B (ru)
AU (1) AU2008312533A1 (ru)
BR (1) BRPI0818334A2 (ru)
CA (1) CA2699354A1 (ru)
CO (1) CO6280484A2 (ru)
CR (1) CR11443A (ru)
DO (1) DOP2010000112A (ru)
EC (1) ECSP10010176A (ru)
GT (1) GT201000100A (ru)
MX (1) MX2010004290A (ru)
PA (1) PA8800601A1 (ru)
RU (1) RU2010119919A (ru)
UA (1) UA99489C2 (ru)
WO (1) WO2009052230A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc DISPOSAL OF SMALL MOLECULES THROUGH AN IMPLANTABLE THERAPEUTIC DEVICE
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410745A (pt) * 2003-05-22 2006-06-27 Abbott Lab inibidores de indazol, benzisoxazol e benzisotiazol quinase
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
US9006240B2 (en) * 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
US7960564B2 (en) 2011-06-14
BRPI0818334A2 (pt) 2017-05-16
PA8800601A1 (es) 2009-05-15
AU2008312533A1 (en) 2009-04-23
EP2195301A1 (en) 2010-06-16
GT201000100A (es) 2012-04-12
CA2699354A1 (en) 2009-04-23
MX2010004290A (es) 2010-04-30
CR11443A (es) 2010-09-27
US20090124815A1 (en) 2009-05-14
JP2011500707A (ja) 2011-01-06
ECSP10010176A (es) 2010-06-29
CN101827824B (zh) 2012-10-03
WO2009052230A1 (en) 2009-04-23
DOP2010000112A (es) 2010-07-15
KR20100085987A (ko) 2010-07-29
UA99489C2 (en) 2012-08-27
CO6280484A2 (es) 2011-05-20
CN101827824A (zh) 2010-09-08

Similar Documents

Publication Publication Date Title
CY1122893T1 (el) Κρυσταλλοι
GB0428514D0 (en) Compounds
EA201000562A1 (ru) Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы
MA33952B1 (fr) Nouveau dérivé 3 -hydroxy- 5-arylisothiazole
TR201820824T4 (tr) IL-12, IL-23 ve/veya IFN-alfa'nın modülatörleri olarak faydalı amid ile sübstitüe edilmiş heterosiklik bileşikler.
NO20093200L (no) Tiazolidinderivater
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
EA200300107A1 (ru) Кристаллические формы трет-бутиламиновой соли периндоприла
GEP20146124B (en) Novel ccr2 receptor antagonists and usage thereof
CY1112780T1 (el) Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
RU2014137257A (ru) Способ получения сульфилиминовых соединений
MY163114A (en) Cyclopentylacrylamide derivative
RU2010119919A (ru) Кристаллические химиотерапевтические средства
MY159183A (en) 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
NO20082118L (no) Heterocykliske CETP-inhibitorer
RU2010119920A (ru) Кристаллические химиотерапевтические средства
WO2011045265A3 (en) Spirocyclic derivatives as histone deacetylase inhibitors
WO2008153027A1 (ja) ピロロキノリン誘導体およびその用途
TW200724539A (en) Benzimidazole derivative and use thereof
DOP2010000116A (es) Productos quimioterapeuticos cristalinos
AR063006A1 (es) Modificacion cristalina de 4-{[(6-cloropiridin-3-il)metil](metil)amino}furan-2(5h)-ona
RU2010119928A (ru) Кристаллические химиотерапевтические средства на основе индазола
BRPI0907732A2 (pt) compostos orgânicos
JP2008509185A5 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130925